• Home
  • »
  • About Alexion

About Alexion

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare diseases. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know there is a significant unmet medical need, and that people's lives depend on our work.

Alexion is the global leader in complement inhibition. We developed and market a treatment for patients suffering from paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS), two severe and life-threatening ultra-rare diseases. The treatment is currently approved in nearly 50 countries for the treatment of PNH and in nearly 40 countries for the treatment of aHUS.

As we continue to expand our operations into additional countries, Alexion is committed to investing in ongoing research and development focused on innovative therapies with life-transforming potential. Currently, Alexion is advancing the most robust rare disease pipeline in the biotech industry, with highly innovative product candidates in multiple therapeutic areas, including a premier global metabolic rare disease franchise with two potential therapies in late-stage development. In addition, as the global leader in complement inhibition, we are strengthening and broadening our portfolio of complement inhibitors across diverse platforms.

Alexion’s work has been recognised many times, including with the prestigious Prix Galien Award for the medical breakthrough of our terminal complement inhibitor, both in the U.S. (2008 Best Biotechnology Product) and France (2009 Best Drug for a Rare Disease). Alexion has also been ranked as one of the top companies on Forbes "World’s Most Innovative Companies" list every year since 2012.

Alexion was founded in 1992 and today has operations to serve patients with severe and life-threatening rare diseases in 50 countries. Learn more about our company history.

For more information about Alexion globally, visit www.alexion.com